Leerink downgraded Aurinia Pharmaceuticals (AUPH) to Market Perform from Outperform with a $16 price target
Claim 50% Off TipRanks Premium and Invest with Confidence
- Unlock hedge-fund level data and powerful investing tools designed to help you make smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis so your portfolio is always positioned for maximum potential
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on AUPH:
- Aurinia Pharmaceuticals upgraded to Buy from Hold at Jefferies
- Aurinia Pharmaceuticals Reports Strong Q3 2025 Earnings
- Aurinia Pharma’s Earnings Call Highlights Growth and Challenges
- Aurinia downgraded to Sector Perform from Outperform at RBC Capital
- Promising Sales and Market Potential of Lupkynis Drive Buy Rating for Aurinia Pharmaceuticals